Skip to main content

Table 2 Multivariate analyses of HDGF and VEGF

From: Novel HDGF/HIF-1α/VEGF axis in oral cancer impacts disease prognosis

Variable

 

DSS

MFS

LRFS

Category

RR

95% CI

p-value

RR

95% CI

p-value

RR

95% CI

p-value

Primary tumor (T)

T1-T2

1

–

0.0001*

1

–

0.0003*

   

T3

1.11

0.40–3.12

 

1.09

0.41–2.88

    

T4

5.98

2.50–14.33

 

4.39

2.00–9.63

    

Histological grade

W-D

1

–

0.0014*

1

–

0.0009*

1

–

0.0981

M-D

3.09

1.11–8.62

 

3.15

1.20–8.23

 

1.247

0.62–2.48

 

P-D

7.50

2.48–22.67

 

6.70

2.50–19.60

 

2.109

1.04–4.27

 

Nodal status (N)

N0

1

–

0.1073

1

–

0.2104

   

N1

2.31

0.90–5.95

 

1.77

0.76–4.10

    

N2

2.98

1.03–8.58

 

2.37

0.88–6.37

    

Post-OP CCRT

Yes

1

–

< 0.0001*

1

–

< 0.0001*

1

–

0.0117*

No

6.89

2.90–16.41

 

5.61

2.54–12.39

 

2.003

1.17–3.44

 

VEGF

Low expression

1

–

0.0183*

1

–

0.0153*

1

–

0.0461*

High expression

4.09

1.27–13.15

 

4.01

1.30–12.30

 

2.100

1.01–3.45

 

HDGF-N

Low expression

1

–

0.0280*

1

–

0.0534

1

–

0.0285*

High expression

3.04

1.13–8.22

 

2.36

0.99–5.62

 

2.141

1.08–4.23

 
  1. Post-OP CCRT, postoperative concurrent chemoradiotherapy; W-D, well differentiated; M-D, moderately differentiated; P-D, poorly differentiated; HDGF-N, nuclear expression of hepatoma-derived growth factor; VEGF, vascular endothelial growth factor; DSS, disease-specific survival; MFS, metastasis-free survival; LRFS, local recurrence-free survival; *, Statistical significance
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us